NanoViricides Inc., a clinical-stage leader in broad-spectrum antiviral drug development, presented at the Pharma Partnering Summit 2025 held at the Hilton Boston Logan Airport in Boston, MA. The presentation, delivered by President and Executive Chairman Dr. Anil R. Diwan, provided updates on the company's drug pipeline and platform technologies available for licensing, highlighting the Phase II clinical-stage antiviral NV-387 and additional drug candidates targeting herpesviruses and HIV.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102438) on November 14, 2025, and is solely responsible for the information contained therein.